CoChat
Sign Up
Cited by 62

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis

Berntsson, Jonna, Eberhard, Jakob, Nodin, Björn, Leandersson, Karin, Larsson, Anna H, Jirström, Karin·2018·OncoImmunology
DOI 10.1080/2162402x.2018.1465165PMC PMC6136864
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2018.1465165

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Immunohistochemical images of PD-1 and PD-L1 staining in colorectal cancer. Sample immunohistochemical images (20x magnification) of (A) PD-1 expression in immune cells, (B) PD-L1 expression in both immune cells and tumour cells, and (C) PD-L1 expression mainly in tumour cells. Unfilled arrows indicate immune cells and filled arrows indicate tumour cells.
Figure 1. Immunohistochemical images of PD-1 and PD-L1 staining in colorectal cancer. Sample immunohistochemical images (20x magnification) of (A) PD-1 expression in immune cells, (B) PD-L1 expression in both immune cells and tumour cells, and (C) PD-L1 expression mainly in tumour cells. Unfilled arrows indicate immune cells and filled arrows indicate tumour cells.CC BY-NC-ND · PubMed Central
Figure 2. Kaplan–Meier estimates of overall survival according to immune cell-specific PD-1 and PDL-1 expression and tumour cell-specific PD-L1 expression, and primary tumour location. Kaplan-Meier analysis of 5-year overall survival in strata of 0–9 %, 10–49 %, and 50–100 % immune cells positive for PD-1 (A, B, C) and PD-L1 (D, E, F) staining, and <1 %, 1–4 %, 5–9 %, 10–49 %, and 50–100 % tumour cells positive for PD-L1 staining (G, H, I), in right-sided (first row) and left-sided (second row) colon cancers, and rectal cancer (third row).
Figure 2. Kaplan–Meier estimates of overall survival according to immune cell-specific PD-1 and PDL-1 expression and tumour cell-specific PD-L1 expression, and primary tumour location. Kaplan-Meier analysis of 5-year overall survival in strata of 0–9 %, 10–49 %, and 50–100 % immune cells positive for PD-1 (A, B, C) and PD-L1 (D, E, F) staining, and <1 %, 1–4 %, 5–9 %, 10–49 %, and 50–100 % tumour cells positive for PD-L1 staining (G, H, I), in right-sided (first row) and left-sided (second row) colon cancers, and rectal cancer (third row).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 51

  1. 10.3322/caac.21262 · DOI
  2. 10.1111/j.1600-065X.2010.00923.x · DOI · Paper page
  3. 10.1158/1078-0432.CCR-06-2746 · DOI · Paper page
  4. 10.1007/s10549-014-2988-5 · DOI
  5. 10.1073/pnas.0406351101 · DOI · Paper page
  6. 10.1056/NEJMoa1200690 · DOI · Paper page
  7. 10.1056/NEJMoa1500596 · DOI · Paper page
  8. 10.1002/ijc.30869 · DOI
  9. 10.1002/ijc.30138 · DOI
  10. 10.1007/s40291-016-0188-1 · DOI
  11. 10.1186/s12943-016-0539-x · DOI
  12. 10.1016/j.ejca.2013.02.015 · DOI
  13. 10.1007/s00262-017-1999-6 · DOI
  14. 10.1038/modpathol.2016.139 · DOI · Paper page
  15. 10.1080/2162402X.2017.1331194 · DOI
  16. 10.1016/j.ejca.2016.06.015 · DOI
  17. 10.1016/j.ejso.2014.11.001 · DOI
  18. 10.1002/jso.20156 · DOI
  19. Hansen IO, 2012, Dan Med J, 59, A4444
  20. 10.1016/j.ejca.2016.10.007 · DOI · Paper page
  21. 10.1016/j.clcc.2016.09.010 · DOI
  22. 10.1093/annonc/mdx119 · DOI
  23. 10.1093/annonc/mdx175 · DOI
  24. Frey DM, 2010, Int J Cancer, 126, 2635, 10.1002/ijc.24989 · DOI
  25. 10.1200/JCO.2008.18.7229 · DOI
  26. 10.1038/srep36956 · DOI
  27. 10.1016/j.ygyno.2016.03.008 · DOI
  28. 10.18632/oncotarget.14519 · DOI
  29. 10.1158/1078-0432.CCR-06-2599 · DOI · Paper page
  30. 10.1073/pnas.192461099 · DOI
  31. 10.1038/nature14011 · DOI · Paper page
  32. 10.1158/1078-0432.CCR-13-3271 · DOI · Paper page
  33. 10.1084/jem.20160801 · DOI
  34. 10.1080/2162402X.2017.1294299 · DOI
  35. 10.1158/2326-6066.CIR-16-0391 · DOI
  36. 10.1038/nature13904 · DOI
  37. 10.1136/gutjnl-2016-311421 · DOI
  38. 10.1038/modpathol.2016.95 · DOI
  39. 10.1038/modpathol.2017.59 · DOI
  40. 10.18632/oncotarget.19318 · DOI
  41. 10.18632/oncotarget.6429 · DOI
  42. 10.1158/0008-5472.CAN-12-2606 · DOI
  43. 10.1136/gutjnl-2011-300865 · DOI
  44. 10.1631/jzus.B0820273 · DOI
  45. 10.1038/srep20090 · DOI
  46. 10.1016/j.molimm.2007.08.013 · DOI
  47. 10.1038/bjc.2011.295 · DOI
  48. 10.1038/bjc.2012.34 · DOI
  49. 10.1111/j.1365-2796.1993.tb00647.x · DOI
  50. 10.1186/1746-1596-8-10 · DOI
  51. 10.1186/2042-6410-4-17 · DOI

Cited by

Sorted by citations

See all 62

Metadata

Authors
Berntsson, J., Eberhard, J., Nodin, B., Leandersson, K., Larsson, A. H., & Jirström, K.
Affiliations
  • Department of Clinical Sciences Lund, Oncology and Pathology, Lund University, Lund, Sweden
  • Cancer Immunology, Department of Translational Medicine, Lund University, Malmö, Sweden
ORCID
Berntsson, Jonna
Venue
OncoImmunology
Publisher
Informa UK Limited
Published
2018-05-02
Pages
e1465165
ISSN
2162-402X
DOI
10.1080/2162402x.2018.1465165
PMC
PMC6136864
Cited by
62
References
7
Language
en
Funders
  • Swedish Cancer Society (CAN 2016/483)
  • Swedish Research Council (2015-03598)
  • Swedish Government Grant for Clinical Research
  • Mrs Berta Kamprad Foundation
  • University Hospital Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review